Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Yasmine C. Abbey"'
Autor:
Juan Juan Yin, Michael L. Beshiri, John B. Tucker, R. Mark Simpson, Carleen Klummp-Thomas, Holly M. Nguyen, Caitlin M. Tice, Shelley E Hoover, Lei Fang, Supreet Agarwal, Paul G. Hynes, Ross Lake, Caitlyn Fuller, Eva Corey, Rajarshi Guha, Yasmine C. Abbey, Craig J. Thomas, Keith H. Jansson, Jacob Cawley, Aian Neil Alilin, John K. Simmons, Xiaohu Zhang, Lauren E. Stahl, David A. Proia, Crystal McKnight, Kathleen Kelly
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Scientific Reports
Scientific Reports
The development of new treatments for castrate resistant prostate cancer (CRPC) must address such challenges as intrinsic tumor heterogeneity and phenotypic plasticity. Combined PTEN/TP53 alterations represent a major genotype of CRPC (25–30%) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c00bce7cd425d8baf006e95f352ade8
http://link.springer.com/article/10.1038/s41598-018-35417-0
http://link.springer.com/article/10.1038/s41598-018-35417-0
Autor:
David A. Proia, Crystal Tran, Yasmine C. Abbey, Juan Juan Yin, Lauren E. Stahl, John B. Tucker, Alilin Aian Neil, Supreet Agarwal, John K. Simmons, Lei Fang, Craig J. Thomas, R. Mark Simpson, Xiahu Zhang, Jacob Cawley, Shelley B. Hoover, Michael L. Beshiri, Keith H. Jansson, Caitlyn Fuller, Holly M. Nguyen, Rajarshi Guha, Eva Corey, Paul G. Hynes, Ross Lake, Kathleen Kelly, Caitlin M. Tice
Publikováno v:
Cancer Research. 78:B018-B018
Androgen-deprivation therapy (ADT) remains the gold-standard therapy for prostate cancer (PrCa), and although ADT is initially effective, most men progress to castrate-resistant prostate cancer (CRPC) within 2-3 years. Advanced CRPC is challenging to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ccf6efc4dfdbd993437b8a21b2410ef
https://doi.org/10.1158/1538-7445.prca2017-b018
https://doi.org/10.1158/1538-7445.prca2017-b018